Revelation Biosciences, Inc. (NASDAQ:REVB) Stock Short Interest Rises 517.6%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 1,581 shares, a growth of 517.6% from the September 15th total of 256 shares. Based on an average daily trading volume, of 36,220 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Institutional Trading of Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC lifted its stake in Revelation Biosciences, Inc. (NASDAQ:REVB) by 192.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 605,702 shares of the company’s stock after acquiring an additional 398,651 shares during the period. Revelation Biosciences accounts for 0.7% of Sabby Management LLC’s portfolio, making the stock its 8th largest position. Sabby Management LLC owned 8.78% of Revelation Biosciences worth $484,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB traded down $0.01 during trading hours on Friday, hitting $0.76. The company’s stock had a trading volume of 24,795 shares, compared to its average volume of 41,350. Revelation Biosciences has a 52 week low of $0.75 and a 52 week high of $5.96. The company has a market capitalization of $3.02 million, a price-to-earnings ratio of -0.06 and a beta of -0.07. The firm’s fifty day moving average price is $0.98 and its 200 day moving average price is $1.05.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.01. On average, equities research analysts predict that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, September 29th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that activate and regulate the body’s innate immune system. Its research is aimed primarily at addressing infectious diseases and inflammatory conditions, particularly those affecting the respiratory system.

The company’s pipeline includes intranasal product candidates designed to stimulate localized immune responses in the nose and airways. Its lead candidate, REVTx-99, has been developed as an investigational therapy for respiratory conditions, including the prevention or reduction of complications associated with severe respiratory infections.